Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease.
David RoofehKevin K BrownElla Annabelle KazerooniDonald P TashkinShervin AssassiFernando J MartinezAthol U WellsGanesh RaghuChristopher P DentonLorinda S ChungAnna-Maria Hoffmann-VoldOliver DistlerKerri A JohannsonYannick AllanoreEric L MattesonLeticia Kawano-DouradoJohn D PaulingJames R SeiboldElizabeth R VolkmannSimon L F WalshChester V OddisEric S WhiteShaney Louise BarrattElana J BernsteinRobyn T DomsicPaul F DellaripaRichard ConwayIvan O RosasNitin BhattVivien HsuFrancesca IngegnoliBashar KahalehPuneet S GarchaNishant GuptaSurabhi KhannaPeter KorstenCelia LinStephen C MathaiVibeke StrandTracy J DoyleVirginia SteenDonald F ZozJuan Gabriel OvallesIgnasi Rodríguez-PintóPadmanabha D ShenoyAndrew LewandoskiElizabeth BelloliAlain LescoatVivek NagarajaWen YeSuiyuan HuangToby M MaherDinesh KhannaPublished in: Rheumatology (Oxford, England) (2022)
Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression, and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.